Table 2.
Comparative effectiveness on Health Assessment Questionnaire scores
| Treatment | No. of studies | No. of participants | Mean difference (95% CrI) | Besta | Prob.db (mean) |
|---|---|---|---|---|---|
| MTX (placebo + MTX) | 8 | 1,004 | - | 0.001 | - |
| CERT + MTX | 1 | 246 | –0.400 (–0.945 to 0.131) | 0.2347 | 0.9572 |
| GOL + MTX | 2 | 200 | –0.125 (–0.571 to 0.379) | 0.0382 | 0.7256 |
| ADAL + MTX | 2 | 274 | –0.354 (–1.557 to 0.839) | 0.3072 | 0.7191 |
| ADAL | 1 | 67 | –0.341 (–2.053 to 1.363) | 0.3778 | 0.6530 |
| GOL | 2 | 200 | –0.082 (–0.689 to 0.526) | 0.0413 | 0.6220 |
CrI, credible interval (the probability to include a parameter); Prob.d, probability distribution; MTX, methotrexate; CERT, certolizumab; GOL, golimumab; ADAL, adalimumab.
a
The relative estimate effect for all treatment comparison ranking.
b
Statistical significance: probability distribution > 0.9.